✦ LIBER ✦

PCN82 COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCER IN GERMANY – AN UPDATED ANALYSIS

✍ Scribed by HG Bischoff; A Hermes; DF Heigener; S Cesaro-Tadic; S Walzer; M Nuijten

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN30 THE COSTS OF TREATING PATIENTS WIT

✍ M Nuijten 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

PCN87 A COST-EFFECTIVENESS ANALYSIS OF B

✍ HG Bischoff; D Heigener; C Wiesner; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

An indirect comparison of bevacizumab pl

✍ John Wen-Cheng CHANG; Sumitra THONGPRASERT; Elaine WRIGHT; Kenneth TSANG; Heung 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 409 KB

PCN14 AN INDIRECT COMPARISON OF THE EFFI

✍ S Walzer; J de Castro Carpeño; A Vergnenegre; C Chouaid; D Heigener; HG Bischoff 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

PCN41 COST-SAVINGS ASSOCIATED WITH BEVAC

✍ D Heigener; HG Bischoff; C Wiesner; R Aultman 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

PCN36 COST ANALYSIS, SAFETY, AND EFFICAC

✍ P. Davey; N. Rajan; Y. Kanivets; H. Barraclough; M. Orlando; A.J. Brnabic; B. Ha 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB